Compass Therapeutics
Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact
Preclinical characterization of NKp30xBCMA, a novel class of NK‐Cell Engagers
Preclinical characterization of NKp30xBCMA, a novel class of NK‐Cell Engagers
Post navigation
Previous Post
Previous
A Novel Class of NK-Cell Engagers Targeting NKp30
Next Post
Next
A versatile platform for efficient affinity optimization of common light chain multi-specific antibodies
Home
About
Platform
Pipeline
Clinical Trials
Join Us
Investors
Contact